1. Home
  2. JF vs BCDA Comparison

JF vs BCDA Comparison

Compare JF & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JF

J and Friends Holdings Limited American Depositary Shares

SELL

Current Price

$0.90

Market Cap

17.4M

Sector

N/A

ML Signal

SELL

Logo BioCardia Inc.

BCDA

BioCardia Inc.

SELL

Current Price

$0.76

Market Cap

15.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JF
BCDA
Founded
2012
N/A
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.4M
15.7M
IPO Year
2017
2009

Fundamental Metrics

Financial Performance
Metric
JF
BCDA
Price
$0.90
$0.76
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $15.50
AVG Volume (30 Days)
5.6K
★ 83.3K
Earning Date
12-01-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.81
$0.66
52 Week High
$1.19
$1.80

Technical Indicators

Market Signals
Indicator
JF
BCDA
Relative Strength Index (RSI) 45.09 34.32
Support Level $0.81 N/A
Resistance Level $1.03 $1.03
Average True Range (ATR) 0.04 0.10
MACD -0.00 -0.01
Stochastic Oscillator 0.13 34.17

Price Performance

Historical Comparison
JF
BCDA

About JF J and Friends Holdings Limited American Depositary Shares

J and Friends Holdings Ltd providing merchant digitalization and commerce-enablement solutions to small and medium enterprises (SME). Its solutions feature critical functionality that SMEs need to engage with consumers, manage their operations, accept payments, and grow their business. Such solutions empower single- and multi-location retailers, restaurants, and other SMEs to compete successfully in an omni-channel market environment by engaging with consumers across online, mobile, and physical channels. The group conducts all of its current operations in Australia and generates revenues from continuing operations are derived from within Australia.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: